XNAS · Healthcare · Biotechnology
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.63 | -0.83 | -31.75% | $0 | ❌ Miss | -0.80% | +4.01% | — |
| 2026-05-13 | Q1 2026 | -1.01 | -0.98 | +2.97% | $0 | ✅ Beat | +0.80% | -17.93% | -25.64% |
| 2026-03-23 |
| Q4 2025 |
| -1.51 |
| -0.48 |
| +68.21% |
| $59,000 |
| ✅ Beat |
| -6.86% |
| +3.19% |
| +7.41% |
| 2025-11-06 | Q3 2025 | -1.65 | -2.19 | -32.73% | $0 | ❌ Miss | — | — | — |
| 2025-08-07 | Q2 2025 | -1.46 | -1.92 | -31.51% | $0 | ❌ Miss | — | — | — |
| 2025-05-12 | Q1 2025 | -1.61 | -1.25 | +22.36% | $0 | ✅ Beat | — | — | — |
| 2025-03-20 | Q4 2024 | -1.39 | 1.72 | +223.74% | $192,000 | ✅ Beat | — | — | — |
| 2024-11-07 | Q3 2024 | -1.45 | -2.83 | -95.17% | $249,000 | ❌ Miss | — | — | — |
Showing last 8 quarters.